Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
411. |
ECCT/17/09/01 | HPTN 084 HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
Principal Investigator(s) 1. Samuel Gurrion Ouma Site(s) in Kenya KISUMU CRS |
01-12-2017 |
View |
412. |
ECCT/17/08/09 | A trial to compare two new combinations of antimalarial drugs with the standard combination of antimalarial drugs in Kenyan children An open-label randomised trial to assess the therapeutic efficacy and tolerability of arterolane-piperaquine plus single low dose primaquine versus arterolane-piperaquine plus mefloquine and single low dose primaquine versus artemether-lumefantrine plus single low dose primaquine in the treatment of uncomplicated falciparum malaria in children in Kenya. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya 1. Kilifi County Hospital - Paediatric Out patient and Inpatient department (Kilifi county) 2. Pingilikani Dispensary (Kilifi county) |
04-01-2018 |
View |
413. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
14-11-2017 |
View |
414. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
02-10-2017 |
View |
415. |
ECCT/17/08/05 | Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho |
12-10-2017 |
View |
416. |
ECCT/17/09/02 | WHO ACTION-I and ACTION-2 Trial A65913: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries to improve newborn outcomes A65916: A multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial of antenatal corticosteroids for women at risk of imminent birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes |
Principal Investigator(s) 1. Frederick Were 2. John Kinuthia 3. Zahida Parveen Qureshi 4. Zahida Parveen Qureshi 5. Zahida Parveen Qureshi Site(s) in Kenya 1. Coast Provincial General Hospital (Mombasa Level 5 Hospital) (Mombasa county) 2. Kiambu Level 4 Hospital (Kiambu county) 3. Thika Level 5 Hospital (Kiambu county) 4. Nakuru Level 5 Hospital (Nakuru county) |
30-04-2018 |
View |
417. |
ECCT/17/08/06 | Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE) Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE) |
Principal Investigator(s) 1. Festus Muigai Njuguna Site(s) in Kenya Homa Bay County Hospital |
03-10-2017 |
View |
418. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
04-10-2017 |
View |
419. |
ECCT/17/08/07 | Tambua Mapema Plus Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus |
Principal Investigator(s) 1. Eduard J Sanders 2. Susan M Graham Site(s) in Kenya KEMRI Mtwapa Research Clinic |
25-08-2017 |
View |
420. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
10-10-2017 |
View |